The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival

Menczer, Joseph; Schreiber, Letizia; Berger, Esther; Levy, Tally

doi:10.1097/igc.0000000000000527

Cited by 2 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brasky et al demonstrated that treatment of aspirin could reduce the risk of EC, especially in estrogen-mediated cases by analyzing 22,268 female Americans after up to 10 years [37]. In clinical studies, the correlation of COX-2 expression and EC patients' prognosis still remains conflicting [38,39]. PGE 2 is associated with both endometrial functions and disorders.…”

Section: Cox-2 and Endometrial Cancermentioning

confidence: 99%

COX-2-PGE2-EPs in gynecological cancers

Yao

Wang

Jeschke

et al. 2020

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors (COXibs) inhibit the progression of endometrial cancer, ovarian cancer and cervical cancer. However, concerning the adverse effects of NSAIDs and COXibs, it is still urgent and necessary to explore novel and specific anti-inflammation targets for potential chemoprevention. The signaling of cyclooxygenase 2-prostaglandin E 2-prostaglandin E 2 receptors (COX-2-PGE 2-EPs) is the central inflammatory pathway involved in the gynecological carcinogenesis. Methods Literature searches were performed to the function of COX-2-PGE 2-EPs in gynecological malignancies. Results This review provides an overview of the current knowledge of COX-2-PGE 2-EPs signaling in endometrial cancer, ovarian cancer and cervical cancer. Many studies demonstrated the upregulated expression of the whole signaling pathway in gynecological malignancies and some focused on the function of COX-2 and cAMP-linked EP2/EP4 and EP3 signaling pathway in gynecological cancer. By contrast, roles of EP1 and the exact pathological mechanisms have not been completely clarified. The studies concerning EP receptors in gynecological cancers highlight the potential advantage of combining COX enzyme inhibitors with EP receptor antagonists as therapeutic agents in gynecological cancers. Conclusion EPs represent promising anti-inflammation biomarkers for gynecological cancer and may be novel treatment targets in the near future.

show abstract

Section: Cox-2 and Endometrial Cancermentioning

confidence: 99%

COX-2-PGE2-EPs in gynecological cancers

Yao

Wang

Jeschke

et al. 2020

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…In osteosarcoma, a recent meta-analysis found that COX-2 expression predicted reduced 2-year overall and disease-free survival, without significant association with age, gender, tumor location, histology, stage, metastasis, or necrosis [27]. COX-2 has been shown to be upregulated in uterine carcinosarcoma [28].…”

Section: Introductionmentioning

confidence: 99%

EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment

Reader

Harper

Legesse

et al. 2019

Cancers

View full text Add to dashboard Cite

The microtubule-stabilizing agent docetaxel in combination with gemcitabine represents one of the most effective regimens against the aggressive gynecologic tumor leiomyosarcoma (LMS). Upregulation of class III β-tubulin has previously been shown to confer taxane resistance in a variety of human cancers. Prostaglandin E2 receptor EP4 is linked to progression of a variety of human cancers and may represent a novel target for tumor inhibition in LMS. We evaluated the hypotheses that EP4 and class III β-tubulin have increased expression in LMS in comparison to normal myometrium or benign tumors and that expression of class III β-tubulin correlates with resistance to taxanes and poor clinical outcome. Gene expression was examined using TCGA data and correlated with clinicopathologic outcome which demonstrated that class III β-tubulin is more highly expressed in more aggressive sarcomas with EP4 being widely expressed in all subtypes of sarcoma. Immunohistochemistry for EP4 and class III β-tubulin was performed on patients with LMS, leiomyomatosis/STUMP, leiomyoma, and normal myometrium. Expression of EP4 and class III β-tubulin were characterized for cell lines SK-UT-1, SK-UT-1B, and PHM-41 and these cell lines were treated with docetaxel alone and in combination with EP4 inhibitors. In taxane-resistant cell lines that overexpress class III β-tubulin and EP4, treatment with EP4 inhibitor resulted in at least 2-fold sensitization to docetaxel. Expression of class III β-tubulin and EP4 in LMS may identify patients at risk of resistance to standard chemotherapies and candidates for augmentation of therapy through EP4 inhibition.

show abstract

The Effect of Cyclooxygenase-2 Expression in Uterine Carcinosarcoma on Survival

Cited by 2 publications

References 14 publications

COX-2-PGE2-EPs in gynecological cancers

COX-2-PGE2-EPs in gynecological cancers

EP4 and Class III β-Tubulin Expression in Uterine Smooth Muscle Tumors: Implications for Prognosis and Treatment

Contact Info

Product

Resources

About